CMPX - Company ID 0001738021
The table below shows Compass Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $850.00K | $0.00 | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $55.97M | $42.34M | $38.12M | - | - | $14.90M |
| SG&A | $16.87M |
Compass Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $850.00K in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $15.13M |
| $12.24M |
| $11.66M |
| $10.93M |
| $12.91M |
| Operating income | -$72.84M | -$56.63M | -$50.36M | -$41.66M | -$81.88M | -$27.81M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $32.00K |
| Net income | -$66.49M | -$49.38M | -$42.49M | -$39.23M | -$82.18M | -$29.50M |
| EPS (diluted) | - | - | - | - | - | - |